Subscribe

Rion Co., Ltd. (6823.T)

JPY3,555.00 +60.00 (+1.72%)
JP JPX Healthcare Medical - Specialties
Address 3-20-41 Higashimotomachi 185-8533
Tokyo, JP
CEO Kiminori Kato
Website rion.co.jp
IPO 2001-01-04
ISIN JP3969700008

Explore sections of this company profile

Description

Rion Co., Ltd. develops, manufactures, sells, and services particle counters, medical equipment, and environmental equipment in Japan. The company’s audiological equipment includes hearing instruments, such as analog and digital BTE, trimmer digital BTE, in-the-ear ready and custom-made, and analog body aid instruments, as well as wireless and waterproof hearing instruments; and medical equipment comprising audiometers and OAE screeners. Its sound and vibration measuring instruments include sound level meters, vibration meters, seismometers, frequency analyzers, microphones and recorders, and other products. The company’s particle counters comprise air and liquid-borne particle counters, and viable particle counters. Its products are primarily used in the applications of environment-related administration, electronics, semiconductors, pharmaceutical, and food manufacturing industries. The company was formerly known as Kobayashi-Riken Seisakusho Ltd. and changed its name to Rion Co., Ltd. in 1960. Rion Co., Ltd. was incorporated in 1944 and is headquartered in Kokubunji, Japan.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
JPY3,555.00 +60.00 (+1.72%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
84.6K
Beta
0.62
Float Shares
7.81M
Free Float %
63.3%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-2.08% -5.61% +4.28% +15.93% +35.56% +32.61% +44.73% +93.11% +39.03% +124.13% +488.33%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
3,555.00
DCF (Unlevered) 8,778.92 +146.9%
DCF (Levered) 8,477.44 +138.5%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
6.28
Safe zone
Piotroski F-Score
3 / 9
Average
MOAT Score
6 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✗
    Revenue growth Medical - Specialties: +8.3%
    +2.2% Q1'26: +7.6% (vs Q1'25)
  • ✓
    EPS growth Medical - Specialties: +10.1%
    +16.9% ★ Q1'26: +50.1% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Medical - Specialties: +51.3%
    +13.3% ★ Q1'26: +0.0% (vs Q1'25)
  • ✗
    EBIT margin Medical - Specialties: +12.6%
    +15.3% ★ Q1'26: +16.3% (vs Q1'25)
  • ✗
    ROIC Medical - Specialties: +6.6%
    +12.7% ★ Q1'26: +16.9% (vs Q1'25)
  • ✗
    Share dilution Medical - Specialties: 0.0%
    +0.1% Q1'26: +0.1% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×
    0.00× ★ Q1'26: 0.00× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.59) × ERP
WACC = 100% × Ke + 0% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 8,778.92 Current price: 3,555.00
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Mar 2015
actual 		Mar 2016
actual 		Mar 2017
actual 		Mar 2018
actual 		Mar 2019
actual 		Mar 2020
actual 		Mar 2021
actual 		Mar 2022
actual 		Mar 2023
actual 		Mar 2024
actual 		Mar 2025
actual 		Mar 2026
1 Rev. Ana.
1 EPS Ana. 		Mar 2027
1 Rev. Ana.
1 EPS Ana. 		Mar 2028
1 Rev. Ana.
1 EPS Ana. 		Mar 2029
1 Rev. Ana.
1 EPS Ana.
Revenue
18.76B
est: 19.00B (-1.3%)
18.86B
est: 19.30B (-2.3%)
19.19B
est: 19.20B (0.0%)
20.35B
est: 20.60B (-1.2%)
21.29B
est: 21.20B (+0.4%)
21.47B
est: 21.30B (+0.8%)
20.47B
est: 21.00B (-2.5%)
22.64B
est: 22.45B (+0.8%)
23.87B
est: 24.00B (-0.5%)
25.73B
est: 26.07B (-1.3%)
27.88B
est: 28.10B (-0.8%)
28.50B
28.50B – 28.50B
+1.4% YoY
29.70B
29.70B – 29.70B
+4.2% YoY
31.20B
31.20B – 31.20B
+5.1% YoY
32.50B
32.50B – 32.50B
+4.2% YoY
EBITDA
2.88B
est: 3.09B (-6.9%)
2.90B
est: 3.14B (-7.6%)
2.50B
est: 3.12B (-20.1%)
3.21B
est: 3.35B (-4.2%)
3.44B
est: 3.45B (-0.2%)
3.26B
est: 3.47B (-5.9%)
2.96B
est: 3.42B (-13.5%)
3.82B
est: 3.65B (+4.5%)
3.59B
est: 3.91B (-8.1%)
4.38B
est: 6.58B (-33.4%)
5.28B
est: 7.09B (-25.6%)
7.19B
7.19B – 7.19B
+1.4% YoY
7.49B
7.49B – 7.49B
+4.2% YoY
7.87B
7.87B – 7.87B
+5.1% YoY
8.20B
8.20B – 8.20B
+4.2% YoY
EBIT
2.26B
est: 2.41B (-6.2%)
2.27B
est: 2.45B (-7.5%)
1.87B
est: 2.44B (-23.5%)
2.56B
est: 2.62B (-2.1%)
2.70B
est: 2.69B (+0.3%)
2.49B
est: 2.71B (-8.2%)
2.22B
est: 2.67B (-16.8%)
3.10B
est: 2.85B (+8.8%)
2.84B
est: 3.05B (-6.8%)
3.47B
est: 4.71B (-26.3%)
4.03B
est: 5.08B (-20.6%)
5.15B
5.15B – 5.15B
+1.4% YoY
5.37B
5.37B – 5.37B
+4.2% YoY
5.64B
5.64B – 5.64B
+5.1% YoY
5.87B
5.87B – 5.87B
+4.2% YoY
Net Income
1.43B
est: 1.52B (-6.1%)
1.59B
est: 1.66B (-3.7%)
1.41B
est: 1.30B (+8.0%)
1.89B
est: 2.21B (-14.5%)
2.00B
est: 2.01B (-0.2%)
1.78B
est: 1.97B (-9.5%)
1.64B
est: 1.76B (-7.2%)
2.23B
est: 2.11B (+5.5%)
1.80B
est: 1.85B (-2.9%)
2.65B
est: 2.37B (+11.8%)
2.86B
est: 3.08B (-7.0%)
3.15B
3.15B – 3.15B
+2.4% YoY
3.50B
3.50B – 3.50B
+11.1% YoY
3.90B
3.90B – 3.90B
+11.4% YoY
4.25B
4.25B – 4.25B
+9.0% YoY
SGA
6.62B
est: 6.37B (+4.0%)
6.48B
est: 6.47B (+0.2%)
7.22B
est: 6.43B (+12.2%)
7.32B
est: 6.90B (+6.1%)
7.57B
est: 7.10B (+6.6%)
7.67B
est: 7.14B (+7.5%)
7.24B
est: 7.04B (+2.9%)
7.35B
est: 7.52B (-2.3%)
7.94B
est: 8.04B (-1.2%)
8.62B
est: 8.50B (+1.4%)
9.18B
est: 9.16B (+0.2%)
9.29B
9.29B – 9.29B
+1.4% YoY
9.68B
9.68B – 9.68B
+4.2% YoY
10.17B
10.17B – 10.17B
+5.1% YoY
10.59B
10.59B – 10.59B
+4.2% YoY
EPS
117.47
est: 123.40 (-4.8%)
130.00
est: 134.40 (-3.3%)
114.73
est: 105.90 (+8.3%)
153.77
est: 179.20 (-14.2%)
163.14
est: 162.90 (+0.1%)
144.96
est: 159.65 (-9.2%)
133.27
est: 143.25 (-7.0%)
181.42
est: 171.65 (+5.7%)
146.33
est: 150.40 (-2.7%)
215.52
est: 192.45 (+12.0%)
232.20
est: 249.60 (-7.0%)
255.50
255.50 – 255.50
+2.4% YoY
283.90
283.90 – 283.90
+11.1% YoY
316.30
316.30 – 316.30
+11.4% YoY
344.70
344.70 – 344.70
+9.0% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-28 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-27 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-26 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-25 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-22 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-21 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-20 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-19 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-18 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-15 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-14 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-13 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-12 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-11 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-08 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-07 A 4/5 5/5 4/5 5/5 1/5 3/5 4/5
2026-05-01 A- 4/5 4/5 3/5 5/5 1/5 4/5 4/5
2026-04-30 A- 4/5 4/5 3/5 5/5 1/5 4/5 4/5
2026-04-28 A 4/5 4/5 3/5 5/5 2/5 4/5 4/5
2026-04-27 A 4/5 4/5 3/5 5/5 2/5 4/5 4/5
2026-04-24 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-23 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-22 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-21 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-20 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-17 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5
2026-04-16 A- 4/5 4/5 3/5 5/5 2/5 3/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
1.17B
OE per share TTM
94.80
Owner's Yield
2.68%
Maintenance CapEx ratio
48.61%
Maint CapEx / Avg PPE
43.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 17 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 WisdomTree Japan SmallCap Dividend Fund DFJ 0.06% 224.3K 0.58%
2 WisdomTree Japan Equity UCITS ETF - USD Acc DXJZ.L 0.02% 165.8K 0.40%
3 WisdomTree Japan Equity UCITS ETF DXJ.L 0.02% 165.8K 0.48%
4 WisdomTree Japan Equity UCITS ETF - CHF Hedged Acc DXJD.SW 0.02% 204.7K 0.45%
5 WisdomTree Japan Equity UCITS ETF - EUR Hedged Acc DXJF.MI 0.02% 188.9K 0.45%
6 WisdomTree Japan Equity UCITS ETF - GBP Hedged DXJP.L 0.02% 221.8K 0.45%
7 WisdomTree Japan Equity UCITS ETF - USD Hedged Acc DXJA.L 0.02% 165.8K 0.48%
8 Avantis International Small Cap Equity ETF AVDS 0.01% 22.3K 0.30%
9 Dimensional - International Small Cap ETF DFIS 0.00% 201.1K 0.39%
10 iShares Core TOPIX ETF 1475.T 0.00% 431.5K 0.05%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
4.32M
Shares Outstanding
12.33M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Alisa Lask Chief Commercial Officer — female
Kiyokatsu Iwahashi Executive Vice President, GM of Environmental Equipment Business & Representative Director — male
Koki Kato President & Representative Director — male
Masaharu Ohya Executive Officer & Head of Research & Development Center — —
Masaki Hirano Executive Officer, Head of Production Division & GM of Material Management — —
Nobuaki Yamaguchi Executive Officer of Production — —
Tadashi Sozaki Executive Officer & Head of Corporate Planning Division — —
Toshiyuki Hasumi Executive Officer, Deputy Head of Corp. Planning Div. and GM of Personnel & General Affairs — —
Toshiyuki Shinozaki GM of Particle Counter Division & Director — male
Yusuke Irie Executive Officer& Head of Corporate Planning Division — —
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Specialties